Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in NF2 and Progressive Vestibular Schwannomas
NCT02129647Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Apr 2014
- Primary completion
- Feb 2019
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib in neurofibromatosis type 2 (NF2), vestibular schwannoma (VS), sponsored by NYU Langone Health. Started Apr 2014; status: completed.
02
Drugs
axitinib
03
Conditions
neurofibromatosis type 2 (NF2)vestibular schwannoma (VS)
Beyond the preview
Go deeper on NCT02129647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129647.